Top

International Ophthalmology

Published in:

01-03-2019 | Original Paper

Tear Martix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Post-Lasik Ectasia

Authors: Mohamed Nagy Elmohamady, Walid Abdelghaffar, Tamer Ibrahim Salem

Published in: International Ophthalmology | Issue 3/2019

Abstract

Purpose

To estimate the concentrations of matrix metalloproteinase-9 (MMP-9) and tissue inhibitors of metalloproteinase-1 (TIMP-1) in the tear film of cases with post-Lasik ectasia (PLE) to spot any role of these mediators.

Settings

Ophthalmology department, Benha University hospitals, Egypt.

Methods

Twelve eyes of 12 patients with PLE, 30 eyes of 30 patients with KC, 25 eyes of 25 subjects with uncomplicated Lasik and finally 25 eyes of 25 healthy subjects as a control group were studied. Subjects with ocular surface diseases, previous ocular surgeries except for Lasik in PLE group and Lasik group, were excluded. All subjects had full ophthalmic examination and Pentacam imaging. The concentration of tear MMP-9 and TIMP-1 was measured by ELISA.

Results

Our results showed a significant elevation in the level of MMP-9 and a significant reduction in the level of TIMP-1 in tear samples from PLE cases (MMP-9 was 59.17 ± 28.15 ng/ml, and TIMP-1 was 110.3 ± 50.6 ng/ml) and also in KC cases (MMP-9 was 53.12 ± 17.35 ng/ml, and TIMP-1 was 105.8 ± 56.3 ng/ml) when compared to post-Lasik group (MMP-9 was 35.65 ± 17.32 ng/ml, and TIMP-1 was 155.2 ± 39.4 ng/ml) and control group (MMP-9 was 31.92 ± 20.78 ng/ml, and TIMP-1 was 162.5 ± 48.2 ng/ml).

Conclusion

The results pointed to potential role of MMP-9 in the pathogenesis of PLE and also referred to a biochemical similarity between PLE and KC. More studies are needed in the future to investigate larger number of tear mediators.

Rebenitsch RL, Kymes SM, Walline JJ, Gordon MO (2011) The lifetime economic burden of keratoconus: a decision analysis using a markov model. Am J Ophthalmol 151:768–773. https://doi.org/10.1016/j.ajo.2010.10.034 PMID: 21310384 CrossRefPubMedPubMedCentral

Jinabhai A, O’Donnell C, Radhakrishnan H (2012) Changes in refraction, ocular aberrations, and corneal structure after suspending rigid gas-permeable contact lens wear in keratoconus. Cornea 31:500–508. https://doi.org/10.1097/ICO.0b013e31820f777b CrossRefPubMed

Padmanabhan P, Reddi SR, Sivakumar PD (2016) Topographic, tomographic, and aberrometric characteristics of post-LASIK ectasia. Optom Vis Sci 93(11):1364–1370CrossRefPubMed

Seiler T, Koufala K, Richter G (1998) Iatrogenic keratectasia after laser in situ keratomileusis. J Refract Surg 14:312Y7

Randelman JB, Russell B, Ward MA, Thompson KP, Stulting RD (2003) Risk factors and prognosis for corneal ectasia after LASIK. Ophthalmology 110:267–275CrossRef

Lema I, Duran JA (2005) Inflammatory molecules in the tears of patients with KC. Ophthalmology 112:654–659CrossRefPubMed

Balasubramanian SA, Mohan S, Pye DC, Willcox MD (2012) Proteases, proteolysis and inflammatory molecules in the tears of people with keratoconus. Acta Ophthalmol 90:e303–e309. https://doi.org/10.1111/j.1755-3768.2011.02369 CrossRefPubMed

Collier SA (2001) Is the corneal degradation in keratoconus caused by matrix-metalloproteinases? Clin Exp Ophthalmol 29:340–344CrossRefPubMed

Shetty R, Ghosh A, Lim RR, Subramani M, Mihir K, Reshma AR, Ranganath A, Nagaraj S, Nuijts RM, Beuerman R, Shetty R, Das D, Chaurasia SS, Sinha-Roy A, Ghosh A (2015) Elevated expression of matrix metalloproteinase-9 and inflammatory cytokines in keratoconus patients is inhibited by cyclosporine A. Invest Ophthalmol Vis Sci 56(2):738–750. https://doi.org/10.1167/iovs.14-14831 CrossRefPubMed

10.

Esquenazi S, Esquenazi I, Grunstein L, He J, Bazan H (2009) Immunohistological evaluation of the healing response at the flap interface in patients With LASIK ectasia requiring penetrating keratoplasty. J Refract Surg (Thorofare, NJ: 1995) 25(8):739–746CrossRef

11.

Hagan S, Martin E, Enríquez-de-Salamanca A (2016) Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalized medicine. EPMA J 7:15. https://doi.org/10.1186/s13167-016-0065-3 CrossRefPubMedPubMedCentral

12.

Pahuja NK, Shetty R, Deshmukh R, Sharma A, Nuijts RMMA, Jhanji V, Sethu S, Ghosh A (2017) In vivo confocal microscopy and tear cytokine analysis in post-LASIK ectasia. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2016-309142 [Epub ahead of print] CrossRefPubMed

13.

Jhanji V, Sharma N, Vajpayee RB (2011) Management of keratoconus: current scenario. Br J Ophthalmol 95:1044–1050CrossRefPubMed

14.

Galvis V, Sherwin T, Tello A, Merayo J, Barrera R, Acera A (2015) Keratoconus: an inflammatory disorder? Eye 29(7):843–859. https://doi.org/10.1038/eye.2015.63 CrossRefPubMedPubMedCentral

15.

Smith V, Rishmawi H, Hussein H, Easty D (2001) Tear film MMP accumulation and corneal disease. Br J Ophthalmol 85(2):147–153. https://doi.org/10.1136/bjo.85.2.147 CrossRefPubMedPubMedCentral

16.

Wisse RP, Kuiper JJ, Gans R, Imhof S, Radstake TR, Van der Lelij A (2015) Cytokine expression in keratoconus and its corneal microenvironment: a systematic review. Ocul Surf 13(4):272–283. https://doi.org/10.1016/j.jtos.2015.04.006 Epub 2015 Jul 30 CrossRefPubMed

17.

Nishtala K, Pahuja N, Shetty R, Nuijts RMMA, Ghosh A (2016) Tear biomarkers for keratoconus. Eye Vis 3:19. https://doi.org/10.1186/s40662-016-0051-9 CrossRef

18.

Sorkhabi R, Ghorbanihaghjo A, Taheri N, Ahoor MH (2015) Tear film inflammatory mediators in patients with keratoconus. Int Ophthalmol 35:467. https://doi.org/10.1007/s10792-014-9971-3 CrossRefPubMed

19.

Pásztor D, Kolozsvári BL, Csutak A, Berta A, Hassan Z, Ujhelyi B, Gogolák P, Fodor M (2016) Tear mediators in corneal ectatic disorders. PLoS ONE 11(4):e0153186. https://doi.org/10.1371/journal.pone.0153186 CrossRefPubMedPubMedCentral

20.

Maguen E, Zorapapel NC, Zieske JD, Ninomiya Y, Sado Y, Kenney MC, Ljubimov AV (2002) Extracellular matrix and matrix metalloproteinase changes in human corneas after complicated laser-assisted in situ keratomileusis (LASIK). Cornea 21(1):95–100CrossRefPubMed

21.

Ji H, Chen A, Zhang W, Gu H, Zhang Z, Fu J (2014) Dynamic changes of tear fluid matrix metralloproteinase-9 within 1 year after laser in situ keratomileusis. Nan Fang Yi Ke Da Xue Xue Bao 34(8):1079–1082PubMed

22.

Maguen E, Rabinowitz YS, Regev L, Saghizadeh M, Sasaki T, Ljubimov AV (2008) Alterations of extracellular matrix components and proteinases in human corneal buttons with INTACS for post-laser in situ keratomileusis keratectasia and keratoconus. Cornea 27(5):565–573. https://doi.org/10.1097/ICO.0b013e318165b1cd CrossRefPubMedPubMedCentral

Title: Tear Martix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Post-Lasik Ectasia
Authors: Mohamed Nagy Elmohamady
Walid Abdelghaffar
Tamer Ibrahim Salem
Publication date: 01-03-2019
Publisher: Springer Netherlands
Published in: International Ophthalmology / Issue 3/2019
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-018-0861-y

At a glance: The STEP trials

Springer Medicine

Tear Martix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Post-Lasik Ectasia

Abstract

Purpose

Settings

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Settings

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Clinical experience with urgent tube shunt implantation through the ciliary sulcus in phakic eyes

Therapeutic potential of curcumin in major retinal pathologies

Modified technique of internal limiting membrane staining in idiopathic macular hole surgery

Bleb-related infections and long-term follow-up after trabeculectomy

Acknowledgement to our reviewers 2018

Ocular surface squamous neoplasia in a setting of fungal keratitis: a rare co-occurrence